Research Use Only. LL-37 is sold as a chemical reagent for in-vitro laboratory research, not for human or veterinary use. It is not a drug, supplement, or compounded preparation. It must be handled by qualified professionals. Wholesale Peptide Supply is not a pharmacy or compounding facility under 503A or 503B.
Wholesale LL-37 — Bulk Research Supply
Also written LL 37 or LL37.
Available sizes
In-stock orders ship same day when paid by 1 pm PT, Mon–Fri. Overnight available.
Buy LL-37 wholesale and in bulk from a US-based research peptide supplier. Every lot is sourced in the USA and third-party tested, with the lab and method on each lot's certificate. Bulk LL-37 is quoted by dose and volume from a 3-kit (30-vial) order minimum, mix and match across doses and compounds; lower prices are earned at 10 kits and again at 100 kits in the order, mix and match.
LL-37 is the only known human cathelicidin peptide, a 37-residue amphipathic helix studied in laboratory models of antimicrobial activity, epithelial signaling and innate immune modulation.

Wholesale Catalog
Available Doses
Published per-vial wholesale pricing for LL-37. Sold in kits of 10 vials with a 3-kit (30-vial) order minimum, mix and match across doses and compounds; lower prices apply at 10 kits and at 1,000+ vials in the order. Contact us for larger or custom-volume quotes — answered the same day. Urgent? Text or call (714) 625-9215 — you’ll reach a real person in the United States, not a chatbot or an overseas call center.
LL-37 5mg
WPSLL5 · CAS 154947-66-7 · Thymic & Antimicrobial Peptides
- 1–9 kits
- $21.85/vial card
$27.31wire/ACH/Zelle - 10–99 kits
- $17.48/vial card
$21.85wire/ACH/Zelle - 100+ kits
- $13.98/vial card
$17.48wire/ACH/Zelle
20% off with cardEarly Black Friday Sale: 20% off every order paid by card
Every product, every volume band — taken off your total at checkout when you choose card. Ends Wed, Nov 25
Sold in kits of 10 vials · 3-kit order minimum, mix and match · price set by the total kits in your order (BAC water not counted)
Questions? Text a rep or call (714) 625-9215 — a real person in the US answers.
Overview
LL-37 is the only known human cathelicidin peptide, a 37-residue amphipathic helix studied in laboratory models of antimicrobial activity, epithelial signaling and innate immune modulation.
History
Identified as the mature peptide released from the human CAMP gene product hCAP18, LL-37 has been extensively characterized in innate immunity research since the mid-1990s.
The only human cathelicidin
LL-37 is the sole cathelicidin-derived antimicrobial peptide found in humans, which is unusual — most mammals carry several — and is a large part of why it is so heavily studied.
It is a 37-residue amphipathic helix carrying a strong net positive charge. Both properties are mechanistically load-bearing: the cationic charge draws it to negatively charged bacterial membranes in preference to the more neutral outer face of mammalian cells, and the amphipathic helix lets it insert into and disrupt the lipid bilayer once there. Selectivity comes from that charge difference rather than from a receptor.
The same molecule also acts in innate immune signalling well beyond membrane disruption — binding bacterial lipopolysaccharide and acting in chemotaxis — which is why it appears in epithelial and wound-model research as readily as in antimicrobial assays.
A practical consequence of the cationic charge: LL-37 adsorbs strongly to negatively charged surfaces, so low-binding labware matters more here than for most peptides, and high-salt buffers can attenuate the membrane activity being measured. Supplied lyophilised, stored at -20°C protected from light, reconstituted solution refrigerated at 2-8°C.
From hCAP18 to LL-37: the sequence, the gene, and the enzyme that releases it
LL-37 is LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES — named for its two N-terminal leucines and its 37 residues. It carries eleven lysines and arginines against five acidic residues, which is where its strong net positive charge comes from, and it contains no cysteine, so none of the disulfide architecture seen in defensins applies here.
It is not synthesized as a free peptide. The single human cathelicidin gene, CAMP, encodes the 170-residue precursor hCAP18 (UniProt P49913): signal peptide at residues 1–30, cathelin-like domain at 31–131, and the antimicrobial segment at 134–170. Sørensen et al. (Blood, 2001, 97:3951–3959) showed that in human neutrophils the precursor is cleaved only after exocytosis, and that of the three azurophil-granule serine proteases tested, proteinase 3 alone performed the cut. Bovine and porcine cathelicidins are processed instead by elastase, so the activating enzyme is species-specific.
The naming happened in two steps. Agerberth et al. (PNAS, 1995, 92:195–199) predicted the peptide from cDNA as FALL-39, a 39-residue form. Gudmundsson et al. (Eur J Biochem, 1996, 238:325–332) then isolated the mature peptide from granulocytes and found it starts two residues later, making it LL-37. UniProt still annotates both boundaries: FALL-39 at 132–170 and LL-37 at 134–170.
Why LL-37's conformation, and its fragments, are experimental variables
LL-37's structure in solution is conditional, which is unusual among the peptides in this catalog and matters when comparing buffers or lots. Johansson et al. (J Biol Chem, 1998, 273:3718–3724) reported that adding anions such as bicarbonate, sulfate or trifluoroacetate at around 15 mM drives the peptide into a helical conformation, that the extent of helicity tracked antibacterial activity, and that helical content falls progressively below pH 5. Trifluoroacetate is a common counter-ion in synthetic peptide salts, so the salt form is part of the experimental condition rather than a footnote.
In lipid micelles the structure is defined. Wang (J Biol Chem, 2008, 283:32637–32643; PDB 2K6O) solved LL-37 by NMR in SDS micelles as a curved helix-bend-helix spanning residues 2–31 with the bend between Gly-14 and Glu-16 and a disordered C-terminal tail, and identified KR-12 (LL-37 residues 18–29) as the shortest fragment retaining antibacterial activity.
The peptide is also a substrate for further processing. Murakami et al. (J Immunol, 2004, 172:3070–3077) found that after secretion onto skin, a serine-protease-dependent mechanism converts LL-37 into shorter peptides, with enhanced antimicrobial action against skin organisms, while the capacity to induce IL-8 release from keratinocytes was lost in the processed forms. UniProt annotates these shorter species on the same precursor: KR-20 at 151–170, KS-30 at 141–170, RK-31 at 140–170, FF-33 at 138–170, LL-29 at 134–162 and LL-23 at 134–156. Work that reports results for "LL-37" in a protease-rich system is therefore often reporting a mixture, which is one reason the full-length synthetic peptide is used as the defined starting material.
Key Areas of Research
- Membrane interaction and antimicrobial mechanism
- Innate immune signaling and chemotaxis
- Epithelial and wound-model research
- Structure-activity work on cathelicidin fragments
References
- Dürr U.H.N. et al. (2006). LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta, 1758(9):1408–1425.
- Vandamme D. et al. (2012). A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol, 280(1):22–35.
LL-37 — Frequently Asked Questions
- What is LL-37?
- LL-37 is the only known human cathelicidin peptide, a 37-residue amphipathic helix studied in laboratory models of antimicrobial activity, epithelial signaling and innate immune modulation.
- What is the CAS number for LL-37?
- The CAS number for LL-37 is 154947-66-7. Its molecular formula is C₂₀₅H₃₄₀N₆₀O₅₃ (MW 4,493.26 g/mol).
- What doses of LL-37 are available wholesale?
- Wholesale Peptide Supply stocks LL-37 in 5mg. Wholesale pricing is provided by quote based on order volume, from a 3-kit (30-vial) order minimum, mix and match across doses and compounds.
- Is LL-37 third-party tested?
- Yes. Every lot of LL-37 is tested by an independent third-party laboratory, and a per-lot Certificate of Analysis documenting identity and purity is included with every order at no charge, issued in the name of Wholesale Peptide Supply.
- Is LL-37 for human use?
- No. LL-37 is sold strictly as a chemical reagent for in-vitro laboratory research and is not for human or veterinary use. Wholesale Peptide Supply is not a pharmacy or compounding facility.
- How do I get wholesale pricing for LL-37?
- Request a quote through our contact form or open a wholesale account. An account manager replies with volume pricing and lead times the same day. For anything urgent, text or call (714) 625-9215 to reach a real person in the US.
- Can I order LL-37 in bulk?
- Yes. LL-37 is available for bulk and wholesale orders, quoted by dose and volume, from a 3-kit (30-vial) order minimum, mix and match across doses and compounds, with lower prices at 10 kits and at 100 kits (1,000 vials) in the order. Submit the doses and quantities you need for a bulk quote.
- How many cathelicidins do humans have compared with other species?
- One. Zanetti's review (Curr Issues Mol Biol, 2005, 7:179–196) records a single cathelicidin gene in humans, monkeys, mice, rats, rabbits, guinea pigs and dogs, three in horses, and a large family in cattle and pigs. Human CAMP maps to chromosome 3, homologous to mouse chromosome 9 (Cnlp, encoding CRAMP) and pig chromosome 13 (PR-39). That single-copy status is why LL-37 carries the whole cathelicidin role in humans while cattle distribute it across indolicidin, the bactenecins and others.
- How does LL-37 differ from the cathelicidins of other mammals?
- Structurally, by class. LL-37 is a linear amphipathic α-helical peptide, the most common cathelicidin type and the only type found in the single-copy species. Cattle and pigs additionally carry structurally different mature peptides: the 13-residue tryptophan-rich indolicidin, proline-rich peptides such as PR-39, Bac5 and Bac7 that are thought to adopt a polyproline II helix, and the disulfide-bridged β-hairpin protegrins PG-1 to PG-5. So "cathelicidin" names a shared precursor architecture, not a shared peptide fold, and a result obtained with protegrin-1 does not transfer to LL-37.
- What is KR-12, and how does it relate to LL-37?
- KR-12 is the 12-residue segment corresponding to LL-37 residues 18–29. Wang (J Biol Chem, 2008) identified it by NMR as the smallest fragment of LL-37 that retains antibacterial activity, describing it as a short three-turn amphipathic helix with selective toxicity toward bacteria over human cells in that work. It is one of several defined LL-37 subfragments — KR-20, KS-30, RK-31 and others — that the literature treats as distinct peptides rather than as LL-37.
- Why is LL-37 stocked in 5 mg rather than the 10 mg used for most compounds here?
- Mass and molarity diverge sharply at this size. LL-37 is 4,493.26 g/mol, so a 5 mg vial holds about 1.11 µmol — less molar material than a 10 mg vial of almost anything else in the catalog, where a 10 mg vial of a heptapeptide such as Semax is around 12 µmol. A 37-residue synthetic peptide is also considerably more demanding to make at purity than a short one. Planning by mass rather than by moles is the common error when moving between the two size classes.
Related Compounds
Thymic & Antimicrobial Peptides
Thymosin Alpha 1
Thymosin Alpha 1 functions as a potent immunomodulator influencing signaling dynamics, cytokine expression, and immune pathway homeostasis.
View details →Thymic & Antimicrobial Peptides
KPV
KPV is a small tripeptide derived from the C-terminus of α-MSH studied for cytokine signaling, NF-κB modulation, and epithelial barrier dynamics.
View details →Thymic & Antimicrobial Peptides
VIP
Vasoactive Intestinal Peptide is a 28-residue basic neuropeptide of the secretin/glucagon superfamily, studied as a VPAC1/VPAC2 receptor agonist in laboratory models of vascular, immune and neuroendocrine signaling.
View details →GLP Series Peptides
GLP-1S
GLP-1S is a synthetic peptide analog that functions as a long-acting pathway agonist, structurally modified for extended half-life and improved target binding affinity. It is studied in preclinical and laboratory models for its ability to activate target pathways and modulate downstream molecular signaling associated with endocrine regulation.
View details →GLP Series Peptides
GLP-2T
GLP-2T is a synthetic peptide that functions as a dual pathway agonist, designed as a once-weekly investigational compound studied in preclinical laboratory models for receptor-mediated signaling and modulation of downstream cascades.
View details →GLP Series Peptides
GLP-3R
GLP-3R is a synthetic investigational peptide developed as a multi-pathway agonist, representing the next generation of metabolic research compounds. It activates multiple target receptor subtypes for broad systemic effects studied in preclinical models.
View details →Secretagogue Peptides
Ipamorelin
Ipamorelin is a synthetic pentapeptide and selective secretagogue-type agonist with minimal off-target pathway interference, used to study endocrine signaling and somatotroph axis modulation.
View details →Structural Peptides
BPC-157
BPC-157 is a synthetic pentadecapeptide composed of 15 amino acids, corresponding to a partial sequence of body protection compound, a protein its discoverers reported isolating from human gastric juice. It has been studied extensively for its potential influence on molecular signaling, structural remodeling, and angiogenic processes.
View details →